| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | Cancer
> Cancer: most types | Regulatory partnership
> Working with regulatory bodies | 100,000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | Respiratory
> Pulmonary hypertension | Regulatory partnership
> Working with regulatory bodies | 10,000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | General health
> Public health | Regulatory partnership
> Contribute to Marketing Authorisation submissions | 100,000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | Cancer
> Cancer: blood | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100,000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | Cancer
> Cancer: blood | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100,000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | Rare
> Fabry disease | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 1,000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancer
> Cancer: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 100,000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Rare
> Rare diseases: most types | Regulatory partnership
> Attend/facilitate meetings with policymakers/regulators | 5,000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | Rare
> Rare diseases: most types | Impacting policy and legislation
> Influence healthcare policy and legislation | 1,000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Liver
> Hepatitis | Impacting policy and legislation
> Influence healthcare policy and legislation | 100,000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | General health
> Public health | Impacting policy and legislation
> Participate in public hearings and consultations | 100,000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Rare
> Rare diseases: most types | Impacting policy and legislation
> Participate in public hearings and consultations | 5,000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 100,000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 100,000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | Endocrine
> Diabetes: type 2 | Pricing and affordability advocacy
> Advocate for fair medicine pricing | 10,000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | General health
> Public health | Pricing and affordability advocacy
> Address cost barriers for low-income and vulnerable people | 100,000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Tracking and monitoring drug pricing/drug shortages | 100,000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancer
> Cancer: most types | Pricing and affordability advocacy
> Tracking and monitoring drug pricing/drug shortages | 100,000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurological
> Multiple sclerosis | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 10,000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurological
> Multiple sclerosis | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 10,000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | Endocrine
> Diabetes: type 2 | Pricing and affordability advocacy
> Advocating for inclusion of product in reimbursement lists/national formularies | 10,000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | Cancer
> Cancer: most types | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 100,000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancer
> Cancer: most types | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 100,000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Rheumatic
> Lupus | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 100,000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Liver
> Hepatitis | Improving access pathways
> Facilitate equitable access to medicines/healthcare | 100,000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Rheumatic
> Lupus | Improving access pathways
> Address disparities in access and management | 100,000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | Skin
> Skin conditions: most types | Evidence-based patient input
> Use patient insights to inform decisions | 100,000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | General health
> Public health | Evidence-based patient input
> Use patient insights to inform decisions | 100,000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancer
> Cancer: most types | Evidence-based patient input
> Use patient insights to inform decisions | 100,000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancer
> Cancer: most types | Evidence-based patient input
> Leverage patient stories and lived-experience narratives | 100,000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancer
> Cancer: most types | Evidence-based patient input
> Conduct surveys/research to generate data | 100,000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancer
> Cancer: most types | Evidence-based patient input
> Conduct surveys/research to generate data | 100,000 | National | Sometimes | 115033327817 |
interactions
actions & advocacy
8 mentions
